ServicenavigationHauptnavigationTrailKarteikarten


Forschungsstelle
EU FRP
Projektnummer
00.0234
Projekttitel
CONTEXTH: New systems of controlled gene expression for improved delivery of therapeutic substances.
Projekttitel Englisch
CONTEXTH: New systems of controlled gene expression for improved delivery of therapeutic substances.

Texte zu diesem Projekt

 DeutschFranzösischItalienischEnglisch
Schlüsselwörter
-
-
-
Anzeigen
Alternative Projektnummern
-
-
-
Anzeigen
Forschungsprogramme
-
-
-
Anzeigen
Kurzbeschreibung
-
-
-
Anzeigen
Partner und Internationale Organisationen
-
-
-
Anzeigen
Abstract
-
-
-
Anzeigen
Datenbankreferenzen
-
-
-
Anzeigen

Erfasste Texte


KategorieText
Schlüsselwörter
(Englisch)
Heterologous gene regulation; tet system; pip system; streptogramin; tetracycline; dual regulation;
Biotechnology; Environmental Protection; Innovation; Technology Transfer; Life Sciences; Medicine; Health; Waste Management
Alternative Projektnummern
(Englisch)
EU project number: QLK3-2000-00721
Forschungsprogramme
(Englisch)
EU-programme: 5. Frame Research Programme - 1.1.3 The 'cell factory'
Kurzbeschreibung
(Englisch)
See abstract
Partner und Internationale Organisationen
(Englisch)
Coordinator: Institut National de la Santé (INSERM) (F)
Abstract
(Englisch)
This proposal wishes to contribute to the development of new treatments against high frequency diseases that are cancers, retinopathies and arteriosclerosis, touching up to 42% of the population.
The proposed approach is to create new gene-transfer systems based on programs of coupled transcriptional and post-transcriptional regulations of gene expression, for an efficient and controlled delivery of active therapeutic agents. Regulatory tools emerging from fundamental research results will allow the creation of new vectors and genetically modified cells efficiently expressing combinations of antiangiogenic agents or growth factors and cytokines.
Antiangiogenesis can target up to 100% of solid tumours and most retinopathies. Angiogenic and anti-inflammatory agents target atheroma plaque, to prevent myocardial infarction. The vectors and cell lines delivering therapeutic substances, tested on animals models, will be commercialised to big industrial companies in Europe that think launching clinical assays and exploit them in a large scale. This program is expected to create a large added value for European community.
Datenbankreferenzen
(Englisch)
Swiss Database: Euro-DB of the
State Secretariat for Education and Research
Hallwylstrasse 4
CH-3003 Berne, Switzerland
Tel. +41 31 322 74 82
Swiss Project-Number: 00.0234